14.58
0.47 (3.33%)
| Previous Close | 14.11 |
| Open | 14.17 |
| Volume | 1,867,960 |
| Avg. Volume (3M) | 1,772,327 |
| Market Cap | 2,431,783,424 |
| Price / Earnings (TTM) | 10.72 |
| Price / Earnings (Forward) | 41.32 |
| Price / Sales | 2.45 |
| Price / Book | 3.21 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 23.64% |
| Operating Margin (TTM) | 2.69% |
| Diluted EPS (TTM) | 1.36 |
| Quarterly Revenue Growth (YOY) | 12.40% |
| Quarterly Earnings Growth (YOY) | 213.90% |
| Total Debt/Equity (MRQ) | 7.10% |
| Current Ratio (MRQ) | 2.38 |
| Operating Cash Flow (TTM) | 157.72 M |
| Levered Free Cash Flow (TTM) | 270.08 M |
| Return on Assets (TTM) | 5.44% |
| Return on Equity (TTM) | 38.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ACADIA Pharmaceuticals Inc. | Bullish | Mixed |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.20 |
|
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 100.31% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Needham, 92.04%) | Buy |
| 28.00 (Cantor Fitzgerald, 92.04%) | Buy | |
| Median | 27.00 (85.19%) | |
| Low | 20.00 (Morgan Stanley, 37.17%) | Hold |
| Average | 25.00 (71.47%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 17.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 Apr 2025 | 28.00 (92.04%) | Buy | 14.10 |
| 27 Feb 2025 | 28.00 (92.04%) | Buy | 19.34 | |
| Morgan Stanley | 07 Mar 2025 | 20.00 (37.17%) | Hold | 17.56 |
| Cantor Fitzgerald | 27 Feb 2025 | 28.00 (92.04%) | Buy | 19.34 |
| HC Wainwright & Co. | 27 Feb 2025 | 27.00 (85.19%) | Buy | 19.34 |
| Deutsche Bank | 11 Feb 2025 | 22.00 (50.89%) | Hold | 18.49 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KIHARA JAMES | - | 14.10 | -1,028 | -14,495 |
| SCHNEYER MARK C. | - | 14.10 | -2,708 | -38,183 |
| Aggregate Net Quantity | -3,736 | |||
| Aggregate Net Value ($) | -52,678 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 14.10 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KIHARA JAMES | Officer | 08 Apr 2025 | Automatic sell (-) | 1,028 | 14.10 | 14,495 |
| SCHNEYER MARK C. | Officer | 08 Apr 2025 | Automatic sell (-) | 2,708 | 14.10 | 38,183 |
| KIHARA JAMES | Officer | 05 Apr 2025 | Option execute | 2,010 | - | - |
| SCHNEYER MARK C. | Officer | 05 Apr 2025 | Option execute | 5,275 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |